Oppenhoff advises Mayo Clinic on Series B financing round in Aignostics

Oppenhoff has provided comprehensive legal advice to Mayo Clinic on the Series B financing round in the AI company Aignostics GmbH.

Aignostics, a leading artificial intelligence company, specialises in turning complex patient data into transformative insights. By combining multimodal clinical data, industry-leading technologies and excellent science, Aignostics develops innovative products and services for the next generation of precision medicine. Founded in 2018, Aignostics is a spin-off of Charité Berlin, one of the largest and most renowned university hospitals in the world.

In addition to Mayo Clinic, other well-known investors participated in the financing round, including lead investor Athos, High-Tech Gründerfonds (HTGF) and existing investors such as Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund and the VC Fonds Technologie managed by IBB Ventures.

With the new financing, Aignostics plans to expand its product range for biopharmaceutical customers, accelerate growth in the US and develop advanced pathology foundation models in close collaboration with Mayo Clinic. These models will be used in particular in the areas of target discovery, translational research and companion diagnostics.

The Oppenhoff team, led by Dr. Markus Rasner, comprised Dr. Carolin Roßkothen, Lisa Zimmermann (all M&A/Venture Capital), Dr. Carsten Bormann (Foreign Trade Law), Dr. Marc Hilber, Jan Tobias Kollakowski (both IT&C), Georg Lecheler, Dr. Patric Mau (both IP), Anja Dombrowsky, Katharina Schäffer (both Employment Law) and Marc Krischer (Tax).

Oppenhoff regularly advises venture capital investors, including the EIC Fund, most recently on the investment in the tech start-up STABL Energy or the investment in the biotech start-up CO2BioClean.

Back to list